| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mark E Bardgett, Tyler Downnen, Casey Crane, Emily C Baltes Thompson, Brittany Muncie, Sara A Steffen, Justin R Yates, James R Paul. Chronic risperidone administration leads to greater amphetamine-induced conditioned place preference. Neuropharmacology. vol 179. 2021-08-27. PMID:32814089. |
the density of forebrain dopamine transporters, a primary target of amphetamine, was also quantified in rats administered risperidone early in life and found to be reduced in the medial anterior, posterior, and ventral caudate nucleus. |
2021-08-27 |
2023-08-13 |
rat |
| Mark E Bardgett, Tyler Downnen, Casey Crane, Emily C Baltes Thompson, Brittany Muncie, Sara A Steffen, Justin R Yates, James R Paul. Chronic risperidone administration leads to greater amphetamine-induced conditioned place preference. Neuropharmacology. vol 179. 2021-08-27. PMID:32814089. |
these results suggest that chronic risperidone treatment modifies later locomotor activity and sensitivity to the reinforcing effects of amphetamine, perhaps via a mechanism related to decreased forebrain dopamine transporter density. |
2021-08-27 |
2023-08-13 |
rat |
| Ana Martínez, Ponciano García-Gutiérrez, Rafael A Zubillaga, Jorge Garza, Rubicelia Varga. Main interactions of dopamine and risperidone with the dopamine D2 receptor. Physical chemistry chemical physics : PCCP. vol 23. issue 26. 2021-08-10. PMID:34159983. |
main interactions of dopamine and risperidone with the dopamine d2 receptor. |
2021-08-10 |
2023-08-13 |
Not clear |
| Ana Martínez, Ponciano García-Gutiérrez, Rafael A Zubillaga, Jorge Garza, Rubicelia Varga. Main interactions of dopamine and risperidone with the dopamine D2 receptor. Physical chemistry chemical physics : PCCP. vol 23. issue 26. 2021-08-10. PMID:34159983. |
in this investigation we perform quantum chemical calculations of two molecules [dopamine and risperidone] within a large cavity of drd2 that represents the binding site of the receptor. |
2021-08-10 |
2023-08-13 |
Not clear |
| Ana Martínez, Ponciano García-Gutiérrez, Rafael A Zubillaga, Jorge Garza, Rubicelia Varga. Main interactions of dopamine and risperidone with the dopamine D2 receptor. Physical chemistry chemical physics : PCCP. vol 23. issue 26. 2021-08-10. PMID:34159983. |
dopamine is an endogenous neurotransmitter and risperidone is a second-generation antipsychotic. |
2021-08-10 |
2023-08-13 |
Not clear |
| Ana Martínez, Ponciano García-Gutiérrez, Rafael A Zubillaga, Jorge Garza, Rubicelia Varga. Main interactions of dopamine and risperidone with the dopamine D2 receptor. Physical chemistry chemical physics : PCCP. vol 23. issue 26. 2021-08-10. PMID:34159983. |
non-covalent interactions of dopamine and risperidone with drd2 are analyzed using the quantum theory of atoms in molecules (qtaim) and the non-covalent interaction index (nci). |
2021-08-10 |
2023-08-13 |
Not clear |
| Ana Martínez, Ponciano García-Gutiérrez, Rafael A Zubillaga, Jorge Garza, Rubicelia Varga. Main interactions of dopamine and risperidone with the dopamine D2 receptor. Physical chemistry chemical physics : PCCP. vol 23. issue 26. 2021-08-10. PMID:34159983. |
there are 22 non-covalent interactions for dopamine and 54 for risperidone. |
2021-08-10 |
2023-08-13 |
Not clear |
| Ana Martínez, Ponciano García-Gutiérrez, Rafael A Zubillaga, Jorge Garza, Rubicelia Varga. Main interactions of dopamine and risperidone with the dopamine D2 receptor. Physical chemistry chemical physics : PCCP. vol 23. issue 26. 2021-08-10. PMID:34159983. |
the electron density evaluated at each critical binding point is small in both systems but it is higher for dopamine than for risperidone, indicating that the interactions of drd2 with the first are stronger than with the second molecule. |
2021-08-10 |
2023-08-13 |
Not clear |
| Ana Martínez, Ponciano García-Gutiérrez, Rafael A Zubillaga, Jorge Garza, Rubicelia Varga. Main interactions of dopamine and risperidone with the dopamine D2 receptor. Physical chemistry chemical physics : PCCP. vol 23. issue 26. 2021-08-10. PMID:34159983. |
however, the binding energy is higher for risperidone (-72.6 kcal mol-1) than for dopamine (-22.8 kcal mol-1). |
2021-08-10 |
2023-08-13 |
Not clear |
| Keisuke Obara, Yuka Matsuoka, Naoya Iwata, Yukako Abe, Yohei Ikegami, Nanako Shioda, Yume Hattori, Shoko Hamamatsu, Kento Yoshioka, Fumiko Yamaki, Kazuhiro Matsuo, Takashi Yoshio, Yoshio Tanak. Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles. Biological & pharmaceutical bulletin. vol 44. issue 8. 2021-08-02. PMID:34334499. |
the remaining nine antipsychotics (pipamperone (a butyrophenone), sulpiride, sultopride, tiapride, nemonapride (benzamides), risperidone, paliperidone (sdas), aripiprazole, and brexpiprazole (dopamine partial agonists)) did not inhibit ach-induced contractions at concentrations up to 10 |
2021-08-02 |
2023-08-13 |
rat |
| Shaul Schreiber, Chaim G Pic. The Opioid Interactions of the Antipsychotic Medications Risperidone and Amisulpride in Mice and Their Potential Use in the Treatment of Other Non-Psychotic Medical Conditions. Cellular and molecular neurobiology. vol 41. issue 5. 2021-05-28. PMID:33184770. |
risperidone is a neuroleptic with a potent dopamine d2 and serotonin 5-ht2 receptor-blocking activity as well as a high affinity for adrenergic and histamine h1 receptors. |
2021-05-28 |
2023-08-13 |
mouse |
| Heidi N Boyda, Amanzo A Ho, Lurdes Tse, Ric M Procyshyn, Jessica W Y Yuen, David D Kim, William G Honer, Alasdair M Bar. Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines. Frontiers in psychiatry. vol 11. 2020-12-19. PMID:33335492. |
dopamine levels increased moderately with olanzapine [+174%], risperidone [+271%], and clozapine [+430%]. |
2020-12-19 |
2023-08-13 |
rat |
| b' \\xc4\\xb0nci Meltem Atay, Bilal Tanritanir, Abdullah Akpinar, Arif Demirda\\xc5\\x9. A Case of Risperidone Induced Stuttering as a Paradox. Noro psikiyatri arsivi. vol 51. issue 4. 2020-10-01. PMID:28360662.' |
risperidone is a strong antagonist of dopamin 2 (d |
2020-10-01 |
2023-08-13 |
Not clear |
| Charanraj Goud Alladi, Anbarasan Mohan, Deepak Gopal Shewade, Ravi Philip Rajkumar, Surendiran Adithan, Karthick Subramania. Risperidone-Induced Adverse Drug Reactions and Role of Journal of pharmacology & pharmacotherapeutics. vol 8. issue 1. 2020-09-30. PMID:28405133. |
risperidone-induced adverse drug reactions and role of to determine the adverse drug reaction (adr) profile of risperidone and their association with dopamine ( |
2020-09-30 |
2023-08-13 |
Not clear |
| Katarzyna Kamińska, Anna Górska, Karolina Noworyta-Sokołowska, Adam Wojtas, Zofia Rogóż, Krystyna Gołembiowsk. The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex. Pharmacological reports : PR. vol 70. issue 5. 2020-04-14. PMID:32002949. |
the effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex. |
2020-04-14 |
2023-08-13 |
rat |
| Nobuhisa Kanahara, Kensuke Yoshimura, Miwako Nakamura, Yasunori Oda, Motoki Watanabe, Masaomi Iy. Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. International clinical psychopharmacology. vol 34. issue 3. 2020-01-23. PMID:30870237. |
metabolism of risperidone by cyp2d6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. |
2020-01-23 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Kensuke Yoshimura, Miwako Nakamura, Yasunori Oda, Motoki Watanabe, Masaomi Iy. Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. International clinical psychopharmacology. vol 34. issue 3. 2020-01-23. PMID:30870237. |
the patients' blood concentrations of risperidone and 9-oh-risperidone were measured, and we compared the occurrence of dopamine supersensitivity psychosis episodes between the groups. |
2020-01-23 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Kensuke Yoshimura, Miwako Nakamura, Yasunori Oda, Motoki Watanabe, Masaomi Iy. Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia. International clinical psychopharmacology. vol 34. issue 3. 2020-01-23. PMID:30870237. |
although our findings were negative, largely because of the small sample size, these results suggest that (1) patients with an impaired functional allele of cyp2d6 may have higher concentrations of risperidone and its active metabolite and that (2) these patients may experience more frequent dopamine supersensitivity psychosis episodes. |
2020-01-23 |
2023-08-13 |
Not clear |
| Lingyue Ma, Qian Xiang, Shuang Zhou, Yunlong Tan, Xiaodan Zhang, Ting Yang, Qiufen Xie, Guangyan Mu, Xia Zhao, Ying Zhou, Suxia Li, Yimin Cu. Association of dopamine D2 receptor gene polymorphisms with prolactin levels related to risperidone treatment: A systematic review and meta-analysis. Journal of clinical pharmacy and therapeutics. vol 44. issue 4. 2019-12-19. PMID:31056781. |
association of dopamine d2 receptor gene polymorphisms with prolactin levels related to risperidone treatment: a systematic review and meta-analysis. |
2019-12-19 |
2023-08-13 |
Not clear |
| Young-Chul Chung, Hong-Bai Eu. Hyperprolactinaemia induced by risperidone. The international journal of neuropsychopharmacology. vol 1. issue 1. 2019-11-20. PMID:11281951. |
risperidone is a potent antagonist of both dopamine (d2) and serotonin (5-ht2) receptors, demonstrating improvement of both positive and negative symptoms and a lower propensity for inducing extrapyramidal symptoms (eps) than typical neuroleptics. |
2019-11-20 |
2023-08-12 |
Not clear |